Aquestive Therapeutics, Inc.

3.21 USD
+0.01 (+0.31%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aquestive Therapeutics, Inc. stock is up 25.39% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 6 July’s closed higher than June. 100% of analysts rate it a buy.

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formant of buprenorphine and naloxone for the. treatment of opioid dependence.